Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

NOVO NORDISK, INC.

Filed by ARNOLD & PORTER KAYE SCHOLER LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 15, 2025
Income
$80,000.00
Expenses
Not reported
Filing UUID
5947f8c4-83ef-46ba-aa70-d620d597e64f
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues related to the 340B Program. Issues related to general compounding.

HCR · Health Issues

Issues related to the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

MMM · Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Literal federal measure citations: H.R. 4231, S. 1973

CSP · Consumer Issues/Safety/Products

Issues related to general compounding.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.